Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®

80

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for patients with cancer, today announced that it has completed a successful Type B Pre-Biologics License Application (BLA) meeting regarding the approval path for Vicinium for the treatment of patients with high-risk, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). The Company has reached alignment with the U.S. Food….

 

http://www.businesswire.com/news/home/20190610005190/en/Sesen-Bio-Announces-Successful-Pre-BLA-Meeting-FDA